| Year |
Citation |
Score |
| 2006 |
Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer. 106: 1353-7. PMID 16475151 DOI: 10.1002/Cncr.21748 |
0.407 |
|
| 2005 |
Weber JS, Snively J, Sian S, Delto J, Groshen S, Gee C, Scotland R. Randomized phase II trial of melanoma peptides with Montanide ISA 51 and different doses of IL-12 with Alum for resected stages IIC/III and IV melanoma Journal of Clinical Oncology. 23: 2506-2506. DOI: 10.1200/Jco.2005.23.16_Suppl.2506 |
0.502 |
|
| 2004 |
Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1007-13. PMID 14981105 DOI: 10.1200/Jco.2004.05.174 |
0.461 |
|
| 2003 |
Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1301-12. PMID 12684398 |
0.502 |
|
| 2003 |
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 864-70. PMID 12610186 DOI: 10.1200/Jco.2003.06.132 |
0.443 |
|
| 2003 |
Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 97: 186-200. PMID 12491520 DOI: 10.1002/Cncr.11045 |
0.535 |
|
| 2001 |
Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3836-47. PMID 11559721 DOI: 10.1200/Jco.2001.19.18.3836 |
0.522 |
|
| 2000 |
Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW, Hall FL. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Research. 60: 3343-7. PMID 10910035 |
0.353 |
|
| 2000 |
Lord RV, Maranzana A, Gee C, Groshen S, Oberg S, Gastal OL, Crookes PF, Bremner CG, Peters JH, Hashemi M, Mason R, DeMeester TR. Risk factors for gastroesophageal reflux disease Gastroenterology. 118: A1267. DOI: 10.1016/S0016-5085(00)80915-4 |
0.393 |
|
| 1999 |
Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunology, Immunotherapy : Cii. 48: 9-21. PMID 10235484 DOI: 10.1007/S002620050543 |
0.457 |
|
| 1998 |
Reles AE, Gee C, Schellschmidt I, Schmider A, Unger M, Friedmann W, Lichtenegger W, Press MF. Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry. Gynecologic Oncology. 71: 3-13. PMID 9784312 DOI: 10.1006/Gyno.1998.5156 |
0.325 |
|
| 1997 |
Simons AJ, Ker R, Groshen S, Gee C, Anthone GJ, Ortega AE, Vukasin P, Ross RK, Beart RW. Variations in treatment of rectal cancer: the influence of hospital type and caseload. Diseases of the Colon and Rectum. 40: 641-6. PMID 9194456 DOI: 10.1007/Bf02140891 |
0.446 |
|
| Show low-probability matches. |